Does Blue Cross Blue Shield of Texas Cover Prolia?

What the BCBSTX Formulary Says About Prolia

BCBSTX places denosumab (Prolia) on a specialty tier in most of its commercial plan formularies. Coverage exists, but it is conditioned on prior authorization approval. The plan's medical policies and drug formularies are updated annually, so the exact tier and cost-share figures on your specific plan document govern.

How to Find Your Plan's Formulary

Every BCBSTX member can look up their formulary at the Blue Cross and Blue Shield of Texas member portal (bcbstx.com). Search for "denosumab" or "Prolia" in the drug search tool. The result will show:

• The tier assignment
• Whether prior authorization (PA) applies
• Whether step therapy (quantity limits or formulary exceptions) applies
• The estimated cost per fill at in-network specialty pharmacies

If your plan is an employer-sponsored self-funded plan, the formulary may differ from standard individual and family plans. Ask your HR benefits administrator for the Summary Plan Description (SPD).

Medical vs. Pharmacy Benefit: Which One Covers Prolia?

This distinction matters for your wallet. Prolia is a provider-administered injection. In most BCBSTX plans it processes under the medical benefit (the same benefit that pays your doctor's office claims) rather than the pharmacy benefit, because a nurse or physician administers it in-office every 6 months.

When Prolia runs through the medical benefit:

• Your medical deductible and medical out-of-pocket maximum apply, not your drug deductible.
• The claim is billed with HCPCS code J0897 (denosumab, 1 mg; Prolia is 60 mg, so 60 units).
• Cost-sharing is typically a coinsurance percentage (commonly 20 to 30% of the allowed amount after the deductible).

Some high-deductible plans and some Medicare Advantage plans route the drug through the pharmacy benefit instead. Check with BCBSTX member services at the number on the back of your ID card to confirm which benefit applies before your first injection.

Prior Authorization Criteria BCBSTX Uses for Prolia

Prior authorization for Prolia under BCBSTX follows criteria grounded in clinical evidence and FDA-approved labeling. Meeting every criterion is necessary for initial approval. Your prescribing provider submits the PA request; your job is to ensure all supporting documentation is in the chart.

Diagnosis and DXA Bone Mineral Density Requirements

BCBSTX typically requires documentation of one of the following:

1. A DXA T-score of <-2.5 at the lumbar spine, total hip, or femoral neck (consistent with osteoporosis per WHO criteria).
2. A DXA T-score between -1.0 and -2.5 (osteopenia range) combined with a FRAX 10-year major osteoporotic fracture probability at or above the threshold recommended by the National Osteoporosis Foundation (NOF) or the American Association of Clinical Endocrinology (AACE) guidelines, typically 20% for major fracture or 3% for hip fracture. AACE/ACE 2020 Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis are available at endocrine.org.
3. A documented low-trauma (fragility) fracture of the hip or spine, regardless of T-score.
4. Bone loss secondary to androgen deprivation therapy (ADT) in prostate cancer or aromatase inhibitor (AI) therapy in breast cancer, with DXA evidence of significant bone loss.

Step Therapy: The Bisphosphonate Requirement

Step therapy is the rule that requires trying a less expensive drug before the insurer will approve the specialty drug. BCBSTX commonly requires a documented trial of an oral bisphosphonate (alendronate, risedronate, or ibandronate) for at least 6 to 12 months before approving Prolia, unless a step-therapy exception applies.

Step-therapy exceptions that BCBSTX typically accepts include:

• Documented intolerance or adverse effects from bisphosphonates (esophageal irritation, atypical femur fracture risk, osteonecrosis of the jaw)
• Inability to sit upright for 30 to 60 minutes post-dose (relevant for patients with severe GERD or neurological conditions)
• Renal impairment with creatinine clearance <35 mL/min (oral bisphosphonates are contraindicated; IV zoledronic acid is an alternative but also requires PA)
• Documented treatment failure defined as continued bone loss or new fracture on bisphosphonate therapy
• A prescriber attestation that bisphosphonate use is clinically contraindicated

The FREEDOM trial (N=7,808 postmenopausal women, 36-month follow-up) showed denosumab reduced new vertebral fractures by 68% and hip fractures by 40% compared with placebo. Cummings SR et al., NEJM 2009. That level of efficacy supports the clinical case for bypassing step therapy when bisphosphonates are genuinely inappropriate.

Documentation the Prescriber Must Submit

Incomplete PA submissions are the most common reason for delay. The PA packet should include:

• Most recent DXA report with T-scores and Z-scores
• FRAX calculation printout (frax-tool.org output is acceptable)
• Bisphosphonate trial history or written clinical rationale for exception
• Complete diagnosis codes (ICD-10: M81.0 for age-related osteoporosis; M80.00 for osteoporosis with current fragility fracture; Z79.51 for long-term glucocorticoid use if applicable)
• Lab results: serum calcium, vitamin D 25-OH level, basic metabolic panel (renal function)
• Prescriber attestation that patient has received calcium and vitamin D supplementation counseling

How Much Does Prolia Cost With BCBSTX Coverage?

Cost-sharing varies by plan type, deductible status, and benefit year timing.

Typical Cost Ranges

Under the medical benefit with an in-network provider, the BCBSTX allowed amount for the denosumab injection (J0897 x 60 units) plus the administration fee commonly falls between $1,200 and $1,800 per injection. Your cost depends on:

• Whether your deductible has been met (if not, you may owe the full allowed amount up to your deductible remaining balance)
• Your coinsurance rate (20% coinsurance on a $1,400 allowed amount = $280 before any out-of-pocket maximum credit)
• Your plan's out-of-pocket maximum (once reached, BCBSTX pays 100%)

For a patient who has already met the deductible on a standard 80/20 PPO plan, the per-injection cost is roughly $240, $360. On a high-deductible health plan (HDHP) early in the benefit year, the same patient might owe $1,200, $1,400.

Amgen's FIRST Co-pay Program

Amgen offers the FIRST (Financial Information, Resources, Support and Tools) program for commercially insured patients. Eligible patients may pay as little as $0 per dose, with Amgen covering up to a specified annual cap. Patients on Medicare, Medicaid, or other federal/state programs are not eligible for manufacturer co-pay assistance due to federal anti-kickback statutes, but they may qualify for Amgen Assist, a separate free-drug program based on income.

Enroll at amgen.com/products/bone-health/prolia.html or call 1-800-772-6436.

The BCBSTX Prior Authorization Process: Step-by-Step

Understanding the exact workflow prevents unnecessary delays.

Step 1: Prescriber Submits the PA Request

Your rheumatologist, endocrinologist, gynecologist, or primary care physician submits a PA request to BCBSTX through the Availity portal or by fax using the BCBSTX specialty drug PA form. The PA form for injectable osteoporosis drugs is available on bcbstx.com under Provider Resources.

Step 2: Initial Decision Timeline

Under Texas law (Texas Insurance Code, Chapter 4201), BCBSTX must issue a decision within 3 business days for standard requests and within 1 business day for urgent/expedited requests. If information is missing, they may issue a "pend" and request additional clinical records, which restarts the clock.

Step 3: Approval, Denial, or Pend

An approval typically covers 12 months (2 doses). After that, a continuation PA is required, usually with a follow-up DXA report showing stable or improved bone mineral density, or clinical documentation that therapy remains appropriate.

A denial will include a denial reason and information on your right to appeal. The denial letter will cite the specific BCBSTX medical policy number that the request did not satisfy.

Step 4: Appealing a Denial

Texas law grants you the right to an internal appeal and, if that fails, an independent review by a Texas Department of Insurance-certified independent review organization (IRO). The timeline:

• Internal appeal decision: within 30 days (standard) or 3 days (expedited)
• IRO review decision: within 15 days (standard) or 3 days (expedited)

According to the Texas Department of Insurance's 2022 Annual Report on HMO/PPO Independent Review, approximately 43% of independent review decisions favored the enrollee across all clinical categories. Your physician's letter should cite the FREEDOM trial data and the relevant AACE or NOF guideline language directly. A well-constructed appeal letter that quotes clinical guidelines increases overturn probability substantially.

The American College of Rheumatology (ACR) recommends denosumab as a first-line option for patients with very high fracture risk. As stated in the 2022 ACR Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis: "Denosumab is conditionally recommended for very high-risk patients when other agents are inappropriate or have failed."

Medicare Advantage and BCBSTX: Different Rules Apply

BCBSTX administers several Medicare Advantage plans in Texas (marketed as Blue Advantage HMO and Blue Advantage Plus PPO). These plans follow CMS rules in addition to BCBSTX-specific formulary decisions.

CMS Step Therapy Protections for Medicare Advantage

The Centers for Medicare and Medicaid Services (CMS) issued guidance in 2018 allowing Medicare Advantage plans to apply step therapy for Part B drugs, including provider-administered drugs like Prolia. However, CMS also requires that step therapy exceptions be evaluated within 72 hours (standard) or 24 hours (expedited), and that exceptions be granted when step therapy is not clinically appropriate. CMS Step Therapy for Part B Drugs guidance is available at cms.gov.

Part B vs. Part D in Medicare Advantage

Under Medicare Advantage Part B, Prolia is covered when administered in a provider's office. The Part B cost-sharing after the deductible is typically 20% of the Medicare-approved amount. For 2025, the Medicare Part B deductible is $257 per year.

The Medicare-allowed amount for J0897 (60 mg denosumab) is set nationally. In 2024, the Medicare Part B payment for Prolia was approximately $1,246 per injection (Average Sales Price plus 6% add-on), making the patient's 20% coinsurance approximately $249 per injection without supplemental coverage (Medigap or employer secondary insurance).

When Prolia Is Denied: Clinical Alternatives BCBSTX May Approve

If Prolia is denied and you need a step-therapy-compliant alternative, the following agents are on BCBSTX formularies with lower prior authorization barriers:

• Alendronate 70 mg weekly (generic): Tier 1 on most plans; preferred first-line per AACE 2020 guidelines for patients without contraindications. Cost is often $4, $10 per month at retail.
• Risedronate 35 mg weekly or 150 mg monthly (generic): Tier 1 to 2; good option if GI tolerability with alendronate is a concern.
• Zoledronic acid 5 mg IV once yearly (Reclast, generic available): Usually Tier 3 medical benefit; preferred for patients unable to take oral bisphosphonates. The HORIZON Key Fracture Trial (N=7,765) showed a 70% reduction in vertebral fracture risk over 3 years. Black DM et al., NEJM 2007.
• Raloxifene 60 mg daily (generic): Tier 2 pharmacy benefit; useful in women with concurrent breast cancer risk concern; 30 to 50% vertebral fracture risk reduction per MORE trial data. Ettinger B et al., JAMA 1999.

If very high fracture risk is documented (T-score <-3.0, multiple prior fractures, or glucocorticoid dose >7.5 mg prednisone/day for >3 months), your prescriber can argue for Prolia as first-line on clinical grounds and cite AACE Guideline Table 4 (2020) in the PA letter.

Special Populations: Glucocorticoid-Induced Osteoporosis and Oncology

Glucocorticoid-Induced Osteoporosis (GIOP)

Prolia holds an FDA-approved indication for GIOP in adults receiving systemic glucocorticoids at a dose of >7.5 mg prednisone/day for >6 months. BCBSTX medical policy typically covers this indication after documenting DXA evidence of bone loss and the glucocorticoid therapy duration and dose. The 2022 ACR GIOP guideline is the most commonly cited document in PA appeals for this indication. Full text at pubmed.ncbi.nlm.nih.gov/35652683.

Hormone Ablation in Cancer

Men on androgen deprivation therapy (ADT) for prostate cancer and women on aromatase inhibitor (AI) therapy for breast cancer experience accelerated bone loss. The FDA approved Prolia for these indications in 2011. BCBSTX covers both under medical necessity criteria that require:

• Documented ADT or AI therapy for active cancer treatment
• DXA T-score <-1.0 or rapid bone loss on serial DXA (loss of >3 to 5% at spine or hip per year)
• Oncologist or treating physician co-signature on the PA

Data from the HALT trial (N=1,468 men on ADT) showed denosumab increased lumbar spine BMD by 5.6% versus -1.0% for placebo at 24 months. Smith MR et al., NEJM 2009.

Practical Tips to Get Prolia Approved Faster

Getting a clean PA approved on the first submission saves 2 to 4 weeks of back-and-forth. These steps help:

1. Ask the ordering provider to call BCBSTX clinical pharmacist line before submission. A 10-minute conversation can identify documentation gaps before the formal request.
2. Request a DXA scan at an accredited ISCD facility. BCBSTX reviewers are less likely to challenge DXA T-scores from International Society for Clinical Densitometry (ISCD)-accredited sites.
3. Document calcium and vitamin D status explicitly. Supplementation is listed in Prolia's FDA labeling as a co-administration requirement. FDA Prolia prescribing information is at accessdata.fda.gov. BCBSTX reviewers check for this.
4. Note the serum calcium value. Hypocalcemia is a contraindication for Prolia; a normal calcium level in the chart removes a common denial flag.
5. If denied, ask the prescriber to invoke a peer-to-peer review with the BCBSTX medical director within 5 business days of the denial. Peer-to-peer review overturns approximately 30 to 40% of initial specialty drug denials before a formal appeal is needed.

Discontinuing Prolia: The Rebound Fracture Risk

One clinical point that affects long-term insurance strategy: stopping Prolia without transitioning to a bisphosphonate carries a documented risk of rapid bone mineral density loss and rebound vertebral fractures. The FDA updated Prolia's label in 2022 to include a warning about multiple vertebral fractures occurring after discontinuation. FDA safety communication available at fda.gov.

Patients whose BCBSTX coverage lapses (job change, plan change, or PA renewal denial) are at clinical risk. Your prescriber should initiate a bridging bisphosphonate (zoledronic acid 5 mg IV is preferred) within 6 months of the last Prolia dose if continuation is interrupted for any reason.